Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.

Cherry angiomas (CAs), also known as Campbell de Morgan spots, are common, benign, well-demarcated cutaneous vascular ...

In the CALIBRATE trial, 76% of encaleret-treated patients normalized both blood and urine calcium at week 24 vs 4% on standard of care, while 91% achieved intact PTH restoration.

Delaying JAK inhibitor initiation yielded higher early antibody responses; earlier initiation linked to earlier improvement in arthritis.

Benefits include improvements for resilience and prosocial behavior, but not symptoms of anxiety or depression.

The FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for pretreated, advanced squamous cell carcinoma of the anal canal based on phase 1/2 GOBLET trial ...

Mean total annual payment increased from $4936 to $6722 and from $2651 to $6811 for those with and without diabetes, respectively.

TG-C is a novel, off-the-shelf cell and gene therapy designed to slow OA progression and provide a non-surgical alternative to standard of care therapies.

For those ultimately able to fill the prescription, study revealed treatment was delayed by 12 days on average.

A new pilot program uses regulated prediction markets and independent data verification to establish public probabilities for ...

Higher diagnostic accuracy reported for dementia experts vs primary care doctors before disclosure of test results, but not after.

HT2A receptor inverse agonist advances in clinical development, with phase 2 trial results anticipated in late 2026.